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Laryngeal Histoplasmosis in patients with Crohn’s Disease undergoing treatment
with HUMIRA (adalimumab): A Case Series
Abstract
The FDA has advocated for increasing awareness of histoplasmosis for patients undergoing TNF
blockers as delay in diagnosis can lead to a poor outcome.1 Laryngeal histoplasmosis is a rare entity that
should be part of the differential diagnosis in patients receiving immune suppression for Crohn’s disease.
Patients with laryngeal histoplasmosis often report hoarseness, mucosal ulcerations, dysphagia, and
odynophagia. We present a series of two cases of laryngeal histoplasmosis in patients with Crohn’s.
These cases illustrate the high index of suspicion required to make the diagnosis of laryngeal
histoplasmosis, especially in the Midwestern United States. Diagnosis is made quickly and costeffectively with proper staining. Delayed diagnosis may lead to dissemination, increased morbidity, and
mortality.
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Introduction
Involvement of the larynx in Crohn’s disease
is rarely described, but may be associated with
symptoms such as dysphonia, dysphagia and
globus sensation, correlating to examination
 
  
formation, laryngeal edema, and vocal
fold hypomobility.1,2 With biologics like
Humira (adalimumab) leading to improved
management of Crohn’s disease, side effects
of immune suppression should be considered
in the differential diagnosis for patients
with symptoms in the upper aerodigestive
tract. The FDA has advocated for increasing
awareness of histoplasmosis for patients
undergoing treatment with TNF blockers
as delay in diagnosis can lead to a poor
outcomes.3
Histoplasmosis, a granulomatous disease
caused by the intracellular organism
Histoplasma capsulatum, is the most
commonly diagnosed endemic mycosis in
the United States, and is most prevalent in
the Ohio and Mississippi River Valleys.3,4
Laryngeal histoplasmosis rarely presents
as an isolated primary lesion and is
more often associated with disseminated
histoplasmosis. Due to its low prevalence,
laryngeal histoplasmosis is often not
included in the differential diagnosis of
many clinicians. In the absence of other
symptoms, such as laryngeal lesions
associated with histoplasmosis, it may
easily be confused with laryngeal Crohn’s,
carcinoma or tuberculosis.4,5 We report two
cases of laryngeal histoplasmosis in patients
with Crohn’s disease receiving adalimumab
therapy and discuss the clinical presentation,
diagnosis, and management of this disease.
Consent was obtained for usage of patient
photographs.

The endoscopic evaluation revealed laryngeal
lesions suspicious for malignancy with
diffuse laryngeal disease with ulceration
and thickening of the supraglottic larynx
(Figure 1A). Biopsy of both patients was
performed to rule out laryngeal malignancy.
One patient was diagnosed after Gomori
Methenamine Silver Stain showed the
presence of intracellular organisms consistent
with histoplasmosis (Figure 2). The second
patient’s diagnosis was delayed until bowel
resection pathology showed disseminated
histoplasmosis. The laryngeal slides were rereviewed in light of the bowel resection and
were indeed positive for fungal elements that
were not diagnosed on the original pathology
slides. Both patients were seen by Infectious
Disease specialists and received antifungal
therapy in addition to discontinuation of
Humira, ultimately leading to resolution
of their symptoms. Follow up endoscopic
examination after two months of therapy
showed marked improvement of laryngeal
lesions (Figure 1B), and complete resolution
     
months for the second.

Discussion
Laryngeal histoplasmosis is a relatively
rare presentation of this mycosis and can

widely vary in its presentation. Typically,
histoplasmosis is inhaled from spores within
        
and can subsequently spread hematologically
to other organ systems. Although the
involvement of the larynx is usually
associated with disseminated disease, there
have been cases reported in the literature of
primary laryngeal histoplasmosis.6
The majority of infected patients are
immunocompetent and asymptomatic
       
illness which resolves without treatment.
Immunocompromised patients, however,
have an increased risk of disseminated
disease, which can progress to fatality if
left untreated.7 Of note, both patients in
this series were receiving adalimumab for
immunosuppressive therapy at the time of
diagnosis.
In patients taking TNF blockers,
histoplasmosis is the most common invasive
fungal infection, and is a more common cause
of serious infections than tuberculosis.3!
        
for developing protective immunity against
Histoplasma capsulatum, and inhibiting this
cytokine can lead to macrophage dysfunction.8
Infections in patients with TNF blockade tend

Case
Two individual patients presented to our
clinic for evaluation of new onset voice
changes with associated odynophagia and
dysphagia. Upon evaluation, it was noted that
both patients were on immunosuppression
medication including Humira (adalimumab)
for Crohn’s disease and both were nonsmokers.
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Figure 1.  
      
A: Pre-antifungal therapy. Moderately edematous and erythematous supraglottic larynx with irregular
mucosal surface and yellow discoloration.
B:       
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Figure 2. Gomori Methamine Stain 400x showing fungal-like yeast forms.

to present with pneumonia or other pulmonary
symptoms and/or signs of progressive
disseminated histoplasmosis, but may also
present with symptoms including skin
necrosis,3 or bowel perforation and laryngeal
lesions as seen in our patients.
Sonkhya et al. reported that the most common
primary laryngeal lesions were located on
the false cords and aryepiglottic folds, with
an endophytic pattern of growth. However,
an exophytic pattern of growth has also been
reported, as have locations involving the
laryngeal surface of the epiglottis, the vocal
cords, cricoid region, and supraglottic region.6
The diagnosis of laryngeal histoplasmosis is
challenging secondary to the varied physical
presentation of the lesions, and their similarity
to malignancy. While suspicion must be high
in an immunocompromised patient, the key
    "
It is imperative to biopsy the lesions
and communicate your suspicions to the
examining pathology, as Grocott and Gomori
silver staining can distinguish the yeast forms.
Therapy for histoplasmosis varies according
to the immune status of the patient, as well
as the extent and severity of the disease.
Intravenous Amphotericin B for 7-10 days
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followed by oral Itraconazole for 9-12 months
is the treatment of choice for disseminated
disease with pulmonary involvement.9 It is not
currently recommended to routinely screen for
histoplasma antigen or to treat patients taking
TNF blockers prophylactically with antifungal therapy.3
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Conclusion
Laryngeal histoplasmosis is an unusual
presentation of this dimorphic fungus, one
that can easily be mistaken for malignancy
     "# 
to have a high index of suspicion of this
disease, especially in immunocompromised
patients and in endemic areas, so that
appropriate testing is performed. Indeed,
   $    
present in patients with Crohn’s disease
undergoing surveillance endoscopy who are
on treatment with Humira (adalimumab).
Delay may lead to further dissemination of
the disease, resulting in increased morbidity
and mortality. It is especially important
to consider this diagnosis if the patient
is immunocompromised and pathologic
examination has ruled out malignancy. 
https://doi.org/10.32873/unmc.dc.gmerj.2.1.009
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